Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Alx Oncology Holdings (ALXO)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ALXO
09/28/2026: ALXO (2-star) is currently NOT-A-BUY. Pass it for now.
ALX Oncology is a clinical-stage biotechnology company developing evorpacept, a therapeutic candidate designed to block the CD47 checkpoint pathway to fight cancer. The company's main strength lies in its proprietary platform, which aims to provide a safer and more effective immune response than current alternatives. Its primary growth story centers on positive clinical trial outcomes that could validate its drug for major cancer indications. However, the company faces significant risks, including the binary nature of clinical results, high cash burn, and intense competition from large pharmaceutical firms. It best suits risk-tolerant investors who monitor clinical trial data as the key development catalyst.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-growth potential linked to clinical breakthroughs but involves substantial binary risk. |
| Momentum investor | Strong fit while signal remains positive | This stock often responds sharply to clinical data releases, which can trigger momentum-based trading cycles. |
| Value investor | Weak fit | The lack of current earnings or commercial revenue makes standard value metrics inapplicable. |
| Dividend investor | Weak fit | The company is in an intensive growth phase and does not pay dividends. |
| Low-risk investor | Weak fit | Clinical-stage biotech investments carry high volatility and are unsuitable for conservative portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical trial results can cause significant, rapid swings in share price. |
| Valuation risk | Medium / high | Valuation is highly speculative and based on future clinical expectations. |
| Competition risk (Immuno-oncology) | High | Larger pharmaceutical companies are aggressively pursuing similar pathways. |
| Business quality | Medium | The company has a focused science-led strategy but lacks a commercial track record. |
| Dividend income | Low / none | Investors should expect zero income from this asset. |
| Execution risk | High | Success depends entirely on the outcomes of complex and lengthy clinical development programs. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit 73.24% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 09/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 181.14M USD | Price to earnings Ratio - | 1Y Target Price 4.6 |
Price to earnings Ratio - | 1Y Target Price 4.6 | ||
Volume (30-day avg) 936.8K shares | Beta 0.4 | 52 Weeks Range 1.05 - 2.66 | Updated Date 09/27/2026 |
52 Weeks Range 1.05 - 2.66 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.15 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development | Research and development of oncology candidates for potential licensing or future commercialization. | The company is currently burning cash to develop a drug and does not yet generate sales. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 71.98M | Price to Sales(TTM) 5085.96 |
Enterprise Value 71.98M | Price to Sales(TTM) 5085.96 | ||
Enterprise Value to Revenue 4287.72 | Enterprise Value to EBITDA -2.35 | Shares Outstanding 138.28M | Shares Floating 94.73M |
Shares Outstanding 138.28M | Shares Floating 94.73M | ||
Percent Insiders 0.89 | Percent Institutions 84.62 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Alx Oncology Holdings
Exchange NASDAQ | Headquarters South San Francisco, CA, United States | ||
IPO Launch date 2020-07-17 | CEO & Director Mr. Jason W. Lettmann | ||
Sector Healthcare | Industry Biotechnology | Full time employees 48 | Website https://www.alxoncology.com |
Full time employees 48 | Website https://www.alxoncology.com | ||
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.